REG - Wellnex Life Limited - Issue of Shares

Wellnex LifeAnnouncement

19/05/2025 07:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250519:nRSS1840Ja&default-theme=true

RNS Number : 1840J  Wellnex Life Limited  19 May 2025

 

 

 

AIM
Announcement
                 19 May 2025

 

 

Wellnex Life Limited (ASX/AIM:WNX)

 

Issue of Shares

 

Wellnex Life Limited ("Wellnex" or the "Company") (ASX/AIM:WNX), an
innovative consumer healthcare business with a track record for developing,
licensing, and marketing products and brands to customers in the growing
healthcare market segment, announces that it has issued 646,153 new ordinary
shares of no par value each in the Company ("Ordinary Shares") at a reference
price of A$0.65 per share, in settlement of  fees in respect of an
undertaking provided by Barclay Pearce Capital Investment Pty Limited to the
Company at the time of its admission to AIM.

 

Further details in respect of the undertaking are set out in the Company's
Admission Document.

 

Admission and Total Voting
Rights

 

Application has been made to the London Stock Exchange for admission of the
646,153 Ordinary Shares to trading on AIM. It is expected that admission will
become effective and dealings in the Ordinary Shares will commence on AIM at
8.00 a.m. on or around 22 May 2025.

 

The new Ordinary Shares will be issued fully paid and will rank pari passu in
all respects with the Company's existing Ordinary Shares.

 

Following Admission, the Company's issued share capital will comprise of
67,771,528 Ordinary Shares, none of which are held in treasury. Accordingly,
the figure of 67,771,528 may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules and the
provisions of the Company's constitution.

 

This AIM announcement has been authorised by the Board of Wellnex Life Limited
(ASX/AIM:WNX).

 

For further information, please contact:

 

Wellnex Life Limited (ASX:WNX)
                                 Reach Markets

George Karafotias or Zack
Bozinovski                           T: 1300 805
9419

Joint Chief Executive
Officers
E: IR@reachmarkets.com.au

P: +61 3 8399 9419

E: george.k@Wellnexlife.com.au (mailto:george.k@Wellnexlife.com.au)

 

UK Investors

 

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson / Robert Collins Tel: +44 (0) 20 7409 3494

 

Orana Corporate LLP (Joint
Broker)
swykeham@oranacorp.com (mailto:swykeham@oranacorp.com)

Sebastian Wykeham

 

S.P. Angel Corporate Finance LLP (Joint Broker)            Tel: +44
(0)20 3470 0470

David Hignell / Vadim Alexandre

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKLBFEELBBBE